$0.07 EPS Expected for Codexis, Inc. (NASDAQ:CDXS) This Quarter

Equities analysts forecast that Codexis, Inc. (NASDAQ:CDXS) will report earnings of $0.07 per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Codexis’ earnings. The highest EPS estimate is $0.07 and the lowest is $0.06. Codexis reported earnings per share of $0.03 during the same quarter last year, which indicates a positive year over year growth rate of 133.3%. The company is scheduled to announce its next quarterly earnings results on Tuesday, February 25th.

According to Zacks, analysts expect that Codexis will report full year earnings of ($0.06) per share for the current year, with EPS estimates ranging from ($0.09) to ($0.02). For the next fiscal year, analysts forecast that the company will post earnings of ($0.02) per share, with EPS estimates ranging from ($0.02) to ($0.01). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Codexis.

Codexis (NASDAQ:CDXS) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.10. The business had revenue of $21.91 million for the quarter, compared to analysts’ expectations of $16.56 million. Codexis had a negative return on equity of 15.24% and a negative net margin of 17.85%.

A number of equities analysts have commented on the company. Zacks Investment Research lowered Codexis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $22.50 target price on shares of Codexis in a research note on Thursday, August 8th. Finally, BidaskClub lowered shares of Codexis from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Codexis presently has a consensus rating of “Buy” and a consensus price target of $21.25.

A number of hedge funds and other institutional investors have recently made changes to their positions in CDXS. Millennium Management LLC grew its stake in Codexis by 192.3% in the third quarter. Millennium Management LLC now owns 283,898 shares of the biotechnology company’s stock valued at $3,893,000 after acquiring an additional 186,763 shares during the period. California State Teachers Retirement System boosted its stake in shares of Codexis by 1.2% during the 3rd quarter. California State Teachers Retirement System now owns 82,381 shares of the biotechnology company’s stock worth $1,130,000 after buying an additional 984 shares during the last quarter. Boston Advisors LLC boosted its stake in shares of Codexis by 42.4% during the 3rd quarter. Boston Advisors LLC now owns 29,361 shares of the biotechnology company’s stock worth $403,000 after buying an additional 8,740 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Codexis by 1,563.8% in the 3rd quarter. SG Americas Securities LLC now owns 171,918 shares of the biotechnology company’s stock valued at $2,358,000 after acquiring an additional 161,585 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Codexis in the third quarter valued at about $421,000. Institutional investors and hedge funds own 84.93% of the company’s stock.

Shares of Codexis stock traded up $0.21 during mid-day trading on Tuesday, reaching $15.52. 7,848 shares of the stock were exchanged, compared to its average volume of 397,476. The company has a market cap of $902.35 million, a price-to-earnings ratio of -73.95 and a beta of -0.02. Codexis has a fifty-two week low of $12.68 and a fifty-two week high of $22.49. The company has a current ratio of 7.37, a quick ratio of 7.34 and a debt-to-equity ratio of 0.25. The firm has a 50-day simple moving average of $14.57 and a 200 day simple moving average of $15.84.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Featured Article: What is a growth and income fund?

Get a free copy of the Zacks research report on Codexis (CDXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.